Cargando…
A Pyridazinone Compound for Effectively Treating Non-alcoholic Steatohepatitis by Targeting THRβ
Developing effective therapies and medicines to conquer nonalcoholic steatohepatitis (NASH) is of great significance for public health and is faced with a major challenge. The activation of the thyroid hormone receptor agonist THRβ could be regulated by target drugs that has brought huge potential t...
Autores principales: | Cheng, Hao, Wang, Xiao-Bo, Zhi, Ying, Liu, Bo, Liu, Na, Li, Meng-Jun, Mu, Yan-Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127185/ https://www.ncbi.nlm.nih.gov/pubmed/35620649 http://dx.doi.org/10.3389/fchem.2022.888587 |
Ejemplares similares
-
Inhibition of Recruitment and Activation of Neutrophils by Pyridazinone-Scaffold-Based Compounds
por: Moniot, Aurélie, et al.
Publicado: (2022) -
3(2H)-pyridazinone derivatives: a new scaffold for novel plant activators
por: Shi, Qinjie, et al.
Publicado: (2019) -
Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Karim, Gres, et al.
Publicado: (2023) -
Ribosome-mediated biosynthesis of pyridazinone oligomers in vitro
por: Lee, Joongoo, et al.
Publicado: (2022) -
Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity
por: Cantini, Niccolo, et al.
Publicado: (2022)